NotesFAQContact Us
Search Tips
Back to results
Peer reviewed Peer reviewed
Direct linkDirect link
ERIC Number: EJ907607
Record Type: Journal
Publication Date: 2010
Pages: 4
Abstractor: ERIC
Reference Count: 0
ISSN: ISSN-0190-2946
Diagnosing Conflict-of-Interest Disorder
Cosgrove, Lisa
Academe, v96 n6 p43-46 Nov-Dec 2010
In June 2010, the Association of American Medical Colleges issued the third and final portion of its conflict-of-interest policy initiatives. The task force on "Conflicts of Interest in Clinical Care" did not mince words when it described the impetus for these initiatives: "It is imperative that the possibility or perception of [financial conflict of interest] be advertently examined and appropriately evaluated to ensure that academic medicine in all of its missions is fundamentally dedicated to the welfare of patients and the improvement of public health." This report is especially timely because of recent questions raised by investigative journalists and policy makers about the extent of industry influence on the diagnostic guidelines of the American Psychiatric Association (APA). Much is at stake: the APA's "Diagnostic and Statistical Manual of Mental Disorders" (DSM) is often referred to as the bible of psychiatric disorders because of its enormous influence on clinical practice, affecting such disparate domains as jurisprudence and insurance claims. In response to concerns about conflicts of interest expressed by researchers, clinicians, patient groups, and even people who served on committees for previous revisions to the DSM, the APA has increased transparency. Specifically, the APA has required all taskforce and panel members to post disclosure statements in which they identify financial ties to industry. The transparency provides an opportunity to assess the subtle but powerful ways pharmaceutical-industry influence may continue to play a role. It is critical not only to look at the proposed changes but also to examine what remains unchanged sixteen years after the "DSM-IV" and a decade after the "DSM-IV-Text Revision" was published. This article describes three areas of concern that emerge from a review of the first draft of the DSM-V and examines how Big Pharma works in subtle but powerful ways inside the pages of the Diagnostic and Statistical Manual of Mental Disorders. It concludes that there exists a social and systemic problem requiring a significant change in the current rules of the game. The rule changes include breaking the "unholy alliance" among the FDA, the APA, and Big Pharma.
American Association of University Professors. 1012 Fourteenth Street NW Suite 500, Washington, DC 20005. Tel: 800-424-2973; Tel: 202-737-5900; Fax: 202-737-5526; e-mail:; Web site:
Publication Type: Journal Articles; Reports - Descriptive
Education Level: N/A
Audience: N/A
Language: English
Sponsor: N/A
Authoring Institution: N/A